This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi
by Zacks Equity Research
Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.
SNYNegative Net Change JNJNegative Net Change LLYNegative Net Change
pharmaceuticals
LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock
by Kinjel Shah
Lilly trades above key SMAs as strong GLP-1 demand, new drugs and pipeline momentum drive shares.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change ADVMNo Net Change
pharmaceuticals
Can Merck's New Products Aid Growth as Keytruda LOE Test Looms?
by Zacks Equity Research
MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.
JNJNegative Net Change MRKNegative Net Change UTHRPositive Net Change
pharmaceuticals
BMY Gains on News of Continuation of Alzheimer's Disease Study
by Zacks Equity Research
Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.
BMYPositive Net Change FOLDPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know
by Zacks Equity Research
ZTS faces steep YTD losses as safety concerns hit key osteoarthritis therapies, forcing revenue cuts while new approvals aim to stabilize growth.
ZTSNegative Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
3 Large Drug Stocks to Watch as the Industry Shows Some Recovery
by Kinjel Shah
In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.
LLYNegative Net Change SNYNegative Net Change JNJNegative Net Change
pharmaceuticals
How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
by Sundeep Ganoria
ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Bayer Stock Up as Government Backs Supreme Court Review in Roundup Case
by Zacks Equity Research
Bayer shares jump after the U.S. Solicitor General backs a Supreme Court review of its Roundup case, adding momentum to its strong 2025 run.
JNJNegative Net Change BAYRYNegative Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain
by Zacks Equity Research
Pacira BioSciences' iovera shows stronger, longer-lasting relief than RFA in a pilot CLBP study, highlighting its tissue-sparing approach and potential spine-care impact.
PCRXNegative Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market?
by Ahan Chakraborty
Eli Lilly cuts Zepbound prices, igniting a fierce battle with Novo Nordisk to expand access and defend share in the obesity market.
NVOPositive Net Change LLYNegative Net Change AMGNNegative Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock?
by Kinjel Shah
VRTX rises 9.2% in three months but trails its industry as mixed new-drug sales and tightened 2025 guidance cloud near-term momentum.
VRTXNegative Net Change MRNAPositive Net Change CRSPPositive Net Change
biotechs pharmaceuticals
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
by Zacks Equity Research
Regeneron teams up with Tessera to advance TSRA-196, aiming to correct the genetic cause of AATD as preclinical data support its move toward trials.
REGNNegative Net Change RHHBYNegative Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business
by Zacks Equity Research
BHC jumps 11% as Solta Medical acquires Wuhan Shibo Zhenmei, gaining full control of its China aesthetics distribution business.
FOLDPositive Net Change ANIPPositive Net Change CRMDPositive Net Change BHCPositive Net Change
biotechnology biotechs medical pharmaceuticals
LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website
by Zacks Equity Research
Eli Lilly trims Zepbound vial prices on LillyDirect, offering lower monthly costs for self-paying patients across multiple doses.
PFEPositive Net Change NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure
by Kinjel Shah
Pfizer's expanding oncology portfolio, rising sales of key therapies, and steady pipeline progress reinforce its long-term cancer strategy momentum.
AZNNegative Net Change BMYPositive Net Change PFEPositive Net Change MRKNegative Net Change
pharmaceuticals
JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis
by Zacks Equity Research
J&J gains EU approval for Imaavy, the first FcRn blocker for adults and adolescents with generalized myasthenia gravis.
JNJNegative Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTPositive Net Change
pharmaceuticals
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules
by Sundeep Ganoria
Shares of vaccine makers slide as an internal FDA memo on vaccine safety and plans for stricter rules spark broad pressure across the overall industry.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXNegative Net Change PCVXNegative Net Change
biotechs messenger-rna pharmaceuticals vaccines
BMY Wins EC Nod for Label Expansion of CAR T Cell Therapy Breyanzi (Revised)
by Zacks Equity Research
Bristol Myers wins EC approval to expand Breyanzi's label, adding MCL patients to its growing roster of European CAR-T indications.
BMYPositive Net Change JNJNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
by Zacks Equity Research
Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
ARCTPositive Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
REGN Gains 21.5% in a Month: Time to Buy, Sell or Hold the Stock?
by Zacks Equity Research
Regeneron's surge is driven by fresh Eylea HD and Libtayo approvals, even as competition and valuation pressures loom.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
VKTX Stock Rises 34% in Three Months: Here's What You Should Know
by Sundeep Ganoria
Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.
PFEPositive Net Change NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
biotechs medical pharmaceuticals
Take the Zacks Approach to Beat the Markets: MBX Biosciences, Garrett Motion & Monster Beverage in Focus
by Santanu Roy
MBX Biosciences' sharp rally highlights how Zacks' stock recommendations outpaced broader market gains across multiple portfolios.
UNHNegative Net Change JNJNegative Net Change PWRPositive Net Change STXPositive Net Change AXSNegative Net Change CACIPositive Net Change CORPositive Net Change MNSTNegative Net Change COHRPositive Net Change NOBLNegative Net Change GTXPositive Net Change MBXNegative Net Change
auto-tires-trucks business-services computers construction consumer-staples insurance medical pharmaceuticals
JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030
by Kinjel Shah
JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.
AZNNegative Net Change JNJNegative Net Change PFEPositive Net Change MRKNegative Net Change
pharmaceuticals
Buy These 5 Best Value Stocks to Make the Most of P/B Ratio
by Kinjel Shah
Discover five low P/B picks like STNE that are undervalued and show solid growth potential based on value-focused filters.
AXSNegative Net Change GLDDNegative Net Change ENSPositive Net Change STNENegative Net Change KROSPositive Net Change
computers construction insurance pharmaceuticals
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
by Ekta Bagri
GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
BMYPositive Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals